Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 4

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 4(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02322333Phase 2Completed

MLD10 in the Prevention of Migraine in Adults

Role: collaborator

NCT01709708Phase 4Completed

Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine

Role: collaborator

NCT00487578Phase 4Terminated

Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

Role: collaborator

NCT00846495Phase 4Completed

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

Role: lead

NCT00397254Phase 4Completed

Two Rizatriptan Prescribing Portions for Treatment of Migraine

Role: lead

NCT00772473Completed

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine

Role: lead

NCT00208065Phase 4Completed

Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers

Role: lead

All 7 trials loaded